- Report
- July 2025
- 184 Pages
Global
From €4124EUR$4,650USD£3,577GBP
- Report
- February 2025
- 200 Pages
Global
From €3982EUR$4,490USD£3,454GBP
- Report
- September 2025
- 150 Pages
Global
From €5189EUR$5,850USD£4,500GBP
From €4346EUR$4,900USD£3,770GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2661EUR$3,000USD£2,308GBP
- Report
- May 2025
- 181 Pages
Global
From €3991EUR$4,500USD£3,462GBP
- Report
- June 2025
- 400 Pages
Global
From €4389EUR$4,949USD£3,807GBP
- Report
- August 2025
- 194 Pages
Global
From €3144EUR$3,545USD£2,727GBP
€3494EUR$3,939USD£3,030GBP
- Report
- August 2025
- 195 Pages
Global
From €3144EUR$3,545USD£2,727GBP
€3494EUR$3,939USD£3,030GBP
- Report
- August 2025
- 191 Pages
Global
From €3144EUR$3,545USD£2,727GBP
€3494EUR$3,939USD£3,030GBP
- Report
- May 2025
- 100 Pages
Global
From €5277EUR$5,950USD£4,577GBP
- Report
- May 2025
- 100 Pages
Global
From €5277EUR$5,950USD£4,577GBP
- Report
- October 2024
- 100 Pages
Global
From €5277EUR$5,950USD£4,577GBP
- Report
- August 2025
- 182 Pages
Global
From €3144EUR$3,545USD£2,727GBP
€3494EUR$3,939USD£3,030GBP
- Report
- August 2025
- 195 Pages
Global
From €3144EUR$3,545USD£2,727GBP
€3494EUR$3,939USD£3,030GBP
- Report
- August 2025
- 188 Pages
Global
From €3144EUR$3,545USD£2,727GBP
€3494EUR$3,939USD£3,030GBP
- Report
- August 2025
- 186 Pages
Global
From €3144EUR$3,545USD£2,727GBP
€3494EUR$3,939USD£3,030GBP
- Report
- March 2025
- 150 Pages
Global
From €3415EUR$3,850USD£2,962GBP
€4302EUR$4,850USD£3,731GBP
- Report
- April 2025
- 250 Pages
Global
From €3982EUR$4,490USD£3,454GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1330EUR$1,500USD£1,154GBP

The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more